A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?

• Rui-Feng Yang,

  Roles Conceptualization, Data curation, Methodology, Writing – original draft

  Affiliation Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China

  ⨯
• Yan Liu,

  Roles Data curation, Methodology

  Affiliation Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China

  ⨯
• Cai-Yan Zhao,

  Roles Data curation, Methodology

  Affiliation Infectious Diseases Department, the Third Hospital of Hebei Medical University, Shijiazhuang, China

  ⨯
• Ya-Xing Ding,

  Roles Validation

  Affiliation Tianjin Center for Diseases Control and Prevention, Tianjin, China

  ⨯
• Yu Chen,

  Roles Data curation, Methodology

  Affiliation Artificial Liver Center, Beijing You’an Hospital, Capital Medical University, Beijing, China

  ⨯
• Ya-Dong Wang,

  Roles Data curation, Methodology

  Affiliation Infectious Diseases Department, the Third Hospital of Hebei Medical University, Shijiazhuang, China

  ⨯
• Zhong-Ping Duan

  Roles Conceptualization, Writing – review & editing

  * E-mail: duan2517@163.com

  Affiliation Artificial Liver Center, Beijing You’an Hospital, Capital Medical University, Beijing, China

  http://orcid.org/0000-0001-7322-6279

  ⨯